

## STATEMENT OF PURPOSE

RS29987 / H0004

The Idaho Board of Pharmacy administers the regulatory provisions of the state's Uniform Controlled Substances Act. This bill mirrors the federal Drug Enforcement Administration (DEA) controlled substance scheduling decisions for 2022, including placing synthetic opioids in Schedule I, a substance to treat insomnia in Schedule IV and an anticonvulsant substance in Schedule V.

## FISCAL NOTE

This legislation will have no impact on the state's General fund or any dedicated fund or federal fund because adding, removing, or rescheduling products to the Controlled Substances Act does not create any new state program and does not compel any state action.

### Contact:

Representative Sue Chew  
(208) 332-1000  
Tim Frost  
Division of Occupational and Professional Licenses  
(208) 577-2491

**DISCLAIMER:** This statement of purpose and fiscal note are a mere attachment to this bill and prepared by a proponent of the bill. It is neither intended as an expression of legislative intent nor intended for any use outside of the legislative process, including judicial review (Joint Rule 18).